| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Prepaid expenses and other current assets | 378,749 | |||
| Vendor deposits | 98,234 | |||
| Cash | 72,086 | |||
| Total current assets | 549,069 | |||
| Vendor deposit | 69,477 | |||
| In-process research and development | 18,647,903 | |||
| Deferred offering costs | 374,662 | |||
| Total assets | 19,641,111 | |||
| Accrued expenses and other current liabilities | 2,915,448 | |||
| Accounts payable | 9,774,230 | |||
| Total current liabilities | 12,689,678 | |||
| Deferred tax liability | 851,659 | |||
| Total liabilities | 13,541,337 | |||
| Treasury stock, at cost, 7 shares at june 30, 2025 and december 31, 2024, | 7,168 | |||
| Accumulated deficit | -117,100,806 | |||
| Preferred stock-Series BPreferred Stock | 1 | |||
| Preferred stock-Series APreferred Stock | 0 | |||
| Common stock | 487 | |||
| Additional paid-in-capital | 123,207,260 | |||
| Total stockholders equity | 6,099,774 | |||
| Total liabilities and stockholders equity | 19,641,111 | |||
ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc. (ZVSA)